Coherus and Junshi Biosciences Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine

Immune-related adverse events (irAEs) (39.7% vs. 18.9%) and Grade 3 irAEs (7.5% vs. 0.7%) were more frequent in the toripalimab arm.